病态药物对慢性阻塞性肺病患者肺功能的影响:随机对照试验的系统审查和元分析
Xiaojun Chen1, Feiyan Hu2, Fang Chai1
1Department of Pharmacy, Sanya People's Hospital, Sanya, China.
Journal of thoracic disease
|August 10, 2023
概括
类药物可以改善肺功能,并减少慢性阻塞性肺病 (COPD) 患者的炎症. 需要进一步的高质量试验来确认COPD治疗中的这些益处.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性阻塞性肺病 (COPD) 是一种具有争议的治疗选择的慢性炎症性肺病.
- 类药物具有抗炎和免疫调节特性,但它们在COPD治疗中的有效性仍然不确定.
研究的目的:
- 通过元分析评估他类药物对被诊断患有COPD的患者的治疗效果.
主要方法:
- 在多个数据库 (PubMed,Cochrane Library,Embase等) 中进行了全面的文献搜索. 截至 2022 年 7 月.
- 包括随机对照研究的选,并评估了偏差风险.
- 用Stata 17.0软件进行了元分析.
主要成果:
- 分析包括10项研究,涉及1463名患者.
- 立方体治疗显著改善FEV1%预测 (预测的强迫呼吸量在第一秒) 和6分钟步行距离 (6MWD).
- 类药物还导致了C反应蛋白 (CRP) 水平和COPD评估测试 (CAT) 评分的降低.
结论:
- 初步发现表明,他类药物可以增强肺功能,减少炎症,并减轻COPD患者的临床症状.
- 目前的证据受到研究质量和数量的限制.
- 需要进行更大规模,更高质量的随机对照试验,以验证他类药物对COPD的这些潜在益处.
相关概念视频
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:26COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244
01:22Chronic Obstructive Pulmonary Disease
1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K